Posthepatectomy but not prehepatectomy chemotherapy was associated with a longer time to recurrence in patients with resectable colorectal liver metastases: Inverse probability of treatment weighting analysis

被引:2
|
作者
Yoshizaki, Yuhi [1 ]
Kawaguchi, Yoshikuni [1 ]
Seki, Yusuke [1 ]
Sasaki, Shu [1 ]
Ichida, Akihiko [1 ]
Akamatsu, Nobuhisa [1 ]
Kaneko, Junichi [1 ]
Arita, Junichi [1 ]
Hasegawa, Kiyoshi [1 ,2 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
关键词
colorectal liver metastases; inverse probability of treatment weighting (IPTW) analysis; multidisciplinary treatment approach; overall survival; recurrence-free survival; HEPATIC RESECTION; PERIOPERATIVE CHEMOTHERAPY; SURVIVAL; CANCER; SURGERY; MULTICENTER; COLON;
D O I
10.1002/jhbp.1314
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundPatients with resectable colorectal liver metastases (CLM) are treated with surgery alone, surgery and posthepatectomy chemotherapy, or prehepatectomy chemotherapy and surgery. The optimal approach in terms of survival is unclear. We compared survival in the three treatment groups using inverse probability of treatment weighting (IPTW) analysis. MethodsData from patients undergoing initial CLM resection in 2005-2018 were obtained from a prospectively maintained database. Our group treated resectable CLM with surgery alone but gradually adopted post- and prehepatectomy chemotherapy for patients with CLM number >= 5 after 2015. IPTW analysis was employed to adjust the characteristics of the three groups. ResultsOf the 439 patients meeting the inclusion criteria, 175 underwent surgery alone, 135 underwent surgery and posthepatectomy chemotherapy, and 129 underwent prehepatectomy chemotherapy and surgery. After the IPTW adjustment, the demographic and clinicopathological characteristics were well balanced. The IPTW analysis revealed that the recurrence-free survival was better in patients undergoing surgery and posthepatectomy chemotherapy than in patients undergoing surgery alone (median recurrence-free survival, 1.3 years vs 0.7 years; P = .018). Overall survival was not significantly different between the three treatment approaches. ConclusionPosthepatectomy but not prehepatectomy chemotherapy prolongs the time to recurrence after curative-intent resection of CLM.
引用
收藏
页码:1006 / 1014
页数:9
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis
    Yue Zhang
    Long Ge
    Jun Weng
    Wen-Yu Tuo
    Bin Liu
    Shi-Xun Ma
    Ke-Hu Yang
    Hui Cai
    World Journal of Clinical Cases, 2021, (22) : 6357 - 6379
  • [22] Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis
    Zhang, Yue
    Ge, Long
    Weng, Jun
    Tuo, Wen-Yu
    Liu, Bin
    Ma, Shi-Xun
    Yang, Ke-Hu
    Cai, Hui
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (22) : 6357 - 6379
  • [23] Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer
    Hebbar, Mohamed
    Pruvot, Francois-Rene
    Romano, Olivier
    Triboulet, Jean-Pierre
    de Gramont, Aimery
    CANCER TREATMENT REVIEWS, 2009, 35 (08) : 668 - 675
  • [24] Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases
    Ninomiya, Mizuki
    Emi, Yasunori
    Motomura, Takashi
    Tomino, Takahiro
    Iguchi, Tomohiro
    Kayashima, Hiroto
    Harada, Noboru
    Uchiyama, Hideaki
    Nishizaki, Takashi
    Higashi, Hidefumi
    Kuwano, Hiroyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2255 - 2264
  • [25] Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases
    Mizuki Ninomiya
    Yasunori Emi
    Takashi Motomura
    Takahiro Tomino
    Tomohiro Iguchi
    Hiroto Kayashima
    Noboru Harada
    Hideaki Uchiyama
    Takashi Nishizaki
    Hidefumi Higashi
    Hiroyuki Kuwano
    International Journal of Clinical Oncology, 2021, 26 : 2255 - 2264
  • [26] Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases
    Gruenberger, B.
    Scheithauer, W.
    Tamandl, D.
    Zielinski, C.
    Schueller, J.
    Gruenberger, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases
    Lee, Jong Min
    Han, Yoon Dae
    Cho, Min Soo
    Hur, Hyuk
    Lee, Kang Young
    Kim, Nam Kyu
    Min, Byung Soh
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (04) : 549 - 559
  • [28] Surgical timing after preoperative chemotherapy is associated with oncologic outcomes in resectable colorectal liver metastases
    Sutton, Thomas L.
    Wong, Liam H.
    Walker, Brett S.
    Dewey, Elizabeth N.
    Eil, Robert L.
    Ibewuike, Uchechukwu
    Chen, Emerson Y.
    Rocha, Flavio G.
    Billingsley, Kevin G.
    Mayo, Skye C.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (08) : 1260 - 1268
  • [29] Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma
    Lorenz, M
    Müller, HH
    Staib-Sebler, E
    Vetter, G
    Gog, C
    Petrowsky, H
    Köhne, CH
    LANGENBECKS ARCHIVES OF SURGERY, 1999, 384 (04) : 328 - 338
  • [30] Neutrophil-to-Lymphocyte Ratio Predicts Recurrence Pattern in Patients with Resectable Colorectal Liver Metastases
    Eden Verter
    Yael Berger
    Gali Perl
    Idit Peretz
    Ana Tovar
    Sara Morgenstern
    Baruch Brenner
    Daniel Benchimol
    Hanoch Kashtan
    Eran Sadot
    Annals of Surgical Oncology, 2021, 28 : 4320 - 4329